Somaxon Slaps Par With 2nd Suit Over Generic Silenor

Law360, New York (May 27, 2011, 9:06 PM EDT) -- Somaxon Pharmaceuticals Inc. hit Par Pharmaceutical Cos. Inc. with a patent infringement suit in Delaware on Thursday, seeking to prevent the release of the generic drug maker's version of Somaxon's prescription insomnia medication Silenor.

Par had informed Somaxon in a letter on May 10 that it was submitting an abbreviated new drug application to the U.S. Food and Drug Administration to get the agency's approval to make and sell 3-milligram and 6-milligram dosages of generic doxepin hydrochloride tablets, which have the same active ingredients and dosage...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.